ArticleFrontiers of medicine2024

Evaluation of molecular residual disease in operable non-small cell lung cancer with gene fusions, MET exon skipping or de novo MET amplification.

Rui Fu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.